[{"address1": "9920 Pacific Heights Boulevard", "address2": "Suite 350", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 704 4660", "website": "https://www.vikingtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR\u00df), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR\u00df for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.", "fullTimeEmployees": 48, "companyOfficers": [{"maxAge": 1, "name": "Dr. Brian  Lian Ph.D.", "age": 58, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 1193748, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gregory S. Zante CPA, CPA", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 713000, "exercisedValue": 20395892, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Marianne  Mancini", "age": 59, "title": "Chief Operating Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 735000, "exercisedValue": 8888907, "unexercisedValue": 636903}, {"maxAge": 1, "name": "Mr. Michael  Morneau", "age": 59, "title": "Vice President of Finance & Administration", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 375333, "exercisedValue": 0, "unexercisedValue": 490518}, {"maxAge": 1, "name": "Dr. Geoffrey E. Barker Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 27.58, "open": 27.66, "dayLow": 26.82, "dayHigh": 28.14, "regularMarketPreviousClose": 27.58, "regularMarketOpen": 27.66, "regularMarketDayLow": 26.82, "regularMarketDayHigh": 28.14, "payoutRatio": 0.0, "beta": 0.666, "forwardPE": -17.913906, "volume": 3779183, "regularMarketVolume": 3779183, "averageVolume": 5725593, "averageVolume10days": 14607230, "averageDailyVolume10Day": 14607230, "bid": 26.93, "ask": 27.19, "bidSize": 13, "askSize": 12, "marketCap": 3041637120, "fiftyTwoWeekLow": 18.92, "fiftyTwoWeekHigh": 81.73, "fiftyDayAverage": 31.1504, "twoHundredDayAverage": 33.0566, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 5276426240, "profitMargins": 0.0, "floatShares": 219960335, "sharesOutstanding": 112445000, "sharesShort": 27513109, "sharesShortPriorMonth": 28599499, "sharesShortPreviousMonthDate": 1752537600, "dateShortInterest": 1755216000, "sharesPercentSharesOut": 0.2447, "heldPercentInsiders": 0.021459999, "heldPercentInstitutions": 0.68371004, "shortRatio": 6.32, "shortPercentOfFloat": 0.2936, "impliedSharesOutstanding": 112445000, "bookValue": 7.081, "priceToBook": 3.820082, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -171547008, "trailingEps": -1.54, "forwardEps": -1.51, "52WeekChange": -0.5367358, "SandP52WeekChange": 0.16844666, "quoteType": "EQUITY", "currentPrice": 27.05, "targetHighPrice": 125.0, "targetLowPrice": 29.0, "targetMeanPrice": 88.77778, "targetMedianPrice": 96.5, "recommendationMean": 1.55556, "recommendationKey": "buy", "numberOfAnalystOpinions": 18, "totalCash": 807724032, "totalCashPerShare": 3.592, "totalDebt": 878000, "quickRatio": 25.257, "currentRatio": 25.86, "debtToEquity": 0.11, "returnOnAssets": -0.14991, "returnOnEquity": -0.19989, "freeCashflow": -102103128, "operatingCashflow": -152535008, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VKTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "postMarketChangePercent": 0.332718, "postMarketPrice": 27.14, "postMarketChange": 0.0900002, "regularMarketChange": -0.530001, "regularMarketDayRange": "26.82 - 28.14", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 5725593, "fiftyTwoWeekLowChange": 8.129999, "fiftyTwoWeekLowChangePercent": 0.42970398, "fiftyTwoWeekRange": "18.92 - 81.73", "fiftyTwoWeekHighChange": -54.680004, "fiftyTwoWeekHighChangePercent": -0.6690322, "fiftyTwoWeekChangePercent": -53.673576, "earningsTimestamp": 1753300800, "earningsTimestampStart": 1761163200, "earningsTimestampEnd": 1761163200, "earningsCallTimestampStart": 1753302600, "earningsCallTimestampEnd": 1753302600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.54, "epsForward": -1.51, "epsCurrentYear": -2.33413, "priceEpsCurrentYear": -11.5889, "fiftyDayAverageChange": -4.100401, "fiftyDayAverageChangePercent": -0.13163237, "twoHundredDayAverageChange": -6.0065994, "twoHundredDayAverageChangePercent": -0.18170652, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1430227800000, "shortName": "Viking Therapeutics, Inc.", "marketState": "CLOSED", "regularMarketChangePercent": -1.92168, "regularMarketPrice": 27.05, "exchange": "NCM", "messageBoardId": "finmb_246791410", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "corporateActions": [], "postMarketTime": 1756511986, "regularMarketTime": 1756497601, "longName": "Viking Therapeutics, Inc.", "cryptoTradeable": false, "displayName": "Viking Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-08-30"}]